367-P: Clinical Characteristics of Type 1 Diabetes and Severe Hypoglycemia in Adult Continuous Glucose Monitor Users

Introduction 1+ SHE/IAH+) and no SHE (0 SHE/IAH+; 0 SHE/IAH-). Participant characteristics were descriptively summarized (mean, standard deviation SD). Results: A total of 1, 847 T1D CGM users responded. The problematic SHE cohort (n=375) compared with the no SHE cohort (n=1, 033) were older (age 49. 0 vs. 45. 6 years), more racially diverse (86. 4% vs. 92. 7% Caucasian), had lower levels of employment (58. 4% vs. 71. 2%), increased report of lower income 50, 000 (25. 1% vs. 16. 9%), and more often reported Medicaid as their primary health insurance (10. 4% vs. 3. 1%). The problematic SHE cohort reported longer duration of T1D (31. 9 SD 16. 0 vs. no SHE 28. 6 SD 14. 8), lower insulin pump use (78. 4% vs. 85. 9%), slightly higher recent HbA1c (6. 9 SD 1. 1 vs. 6. 6 SD 0. 9), with more participants with HbA1c ≥7% (42. 4% vs. 31. 3%). More T1D-related complications were reported in the problematic SHE vs. no SHE cohort (retinopathy 28. 3% vs. 21. 5%; neuropathy 24. 5% vs. 10. 5%; nephropathy 8. 3% vs. 4. 5%; gastroparesis 19. 5% vs. 6. 5%; and cardiovascular disease 12. 5% vs. 5. 5%). Based on BMI calculated from reported height and weight, 60% of participants were overweight or obese across all cohorts. Conclusion: Findings suggest those who experience SHE have higher clinical burden and lower socioeconomic status, highlighting the need for innovative approaches to management for these individuals. Disclosure P. Callahan: Employee; Vertex Pharmaceuticals Incorporated. A. Boateng-Kuffour: Employee; Vertex Pharmaceuticals Incorporated. K. Chandarana: Employee; Vertex Pharmaceuticals Incorporated. Stock/Shareholder; Vertex Pharmaceuticals Incorporated, Novo Nordisk, Eli Lilly and Company. T. Gupta: Employee; Vertex Pharmaceuticals Incorporated. L. Chen: None. C. S. Kelly: None. H. Nguyen: None. K. S. M. Chapman: None. E. M. Cornelius: None. W. Wolf: None. W. H. Polonsky: Research Support; Abbott Diagnostics, Dexcom, Inc. Consultant; Eli Lilly and Company, Sanofi. Advisory Panel; embecta. Consultant; Vertex Pharmaceuticals Incorporated. Advisory Panel; 9am Health. Funding Vertex Pharmaceuticals Incorporated